Brokerage firm BMO Capital Downgrades its rating on Regulus Therapeutics Inc(NASDAQ:RGLS). The shares have been rated Market Perform. Previously, the analysts had a Outperform rating on the shares. The rating by BMO Capital was issued on Jun 28, 2016.
In a different note, On Jun 7, 2016, Chardan Capital said it Maintains its rating on Regulus Therapeutics Inc. In the research note, the firm Raises the price-target to $15.00 per share. The shares have been rated ‘Buy’ by the firm.
Regulus Therapeutics Inc (RGLS) made into the market gainers list on Fridays trading session with the shares advancing 11.07% or 0.32 points. Due to strong positive momentum, the stock ended at $3.21, which is also near the day’s high of $3.287. The stock began the session at $2.89 and the volume stood at 17,85,750 shares. The 52-week high of the shares is $11.59 and the 52 week low is $2.44. The company has a current market capitalization of $169 M and it has 5,27,81,008 shares in outstanding.
Regulus Therapeutics Inc(RGLS) last announced its earnings results on May 2, 2016 for Fiscal Year 2016 and Q1.Company reported revenue of $489.00K. Analysts had an estimated revenue of $2.62M. Earnings per share were $-0.40. Analysts had estimated an EPS of $-0.33.
Several Insider Transactions has been reported to the SEC. On Mar 7, 2016, Joseph P Hagan (COO) purchased 10,000 shares at $7.19 per share price.Also, On Aug 13, 2015, Mark G Foletta (director) purchased 10,000 shares at $7.64 per share price.On Jul 21, 2015, William H Rastetter (director) purchased 100,000 shares at $10.16 per share price, according to the Form-4 filing with the securities and exchange commission.
Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state. Its microRNA provides therapeutic approach for treating diseases. The Companys Regulus microMarkers division is focused on identifying microRNAs as biomarkers of human disease which is designed to support its therapeutic pipeline collaborators and strategic partners. Its development programs include microRNA target miR-122 miR-21 RG-012 miR-103/107 miR-19 miR-10b and miR-221. The Company under the Clinical Map Initiative is focused on advancing its clinical-stage programs RG-101 and RG-012 in 2015. The Company achieved human proof-of-concept with RG-101 in HCV.